With the vigorous development of the biopharmaceutical industry, the pace of innovative achievements is accelerating in Beijing Economic-Technological Development Area (Beijing E-Town). In the first half of the year, 106 first-class new drugs have been approved for clinical use in the Beijing E-Town, accounting for 57 percent of the total in Beijing.

Immunotech Biopharm, with its intelligent manufacturing factory spanning nearly 30,000 square meters, has addressed the key technological challenges in large-scale production and quality inspection within China's cell therapy industry. It has achieved the large-scale production of immunotherapy drugs.

In February of this year, the aT19 injection developed by Immunotech Biopharm obtained approval for clinical trials, officially entering the clinical trial stage. "The aT19 injection is mainly suitable for patients with relapsed or refractory B-cell acute lymphoblastic leukemia aged 25 and below, aiming to address treatment bottlenecks and potentially achieve tumor remission,"  the person in charge of the company explained.

In addition, as an innovative biopharmaceutical company focusing on the research and development of antibody drugs in the fields of autoimmune diseases and oncology, MAB Works has developed a differentiated pipeline composed of seven clinical-stage investigational drugs and several representative preclinical investigational drugs.

According to Wang Tian, secretary of the Board of MAB Works, MIL62 is a new generation CD20 antibody developed independently by the company. The treatment of primary membranous nephropathy (PMN) with MIL62 was designated as a "breakthrough therapy" drug variety by the National Medical Products Administration in June 2023, making it the first domestically produced drug to receive this qualification in the field of nephropathy treatment.

Currently, the Beijing E-Town has already gathered over 4,800 biopharmaceutical companies. In the future, more innovative drugs are expected to emerge from the area, benefiting patients worldwide.